Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.

By: Robbins LLP via GlobeNewswire

June 13, 2025 at 20:28 PM EDT

SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors Regarding the Viability and Efficacy of RP-A501

According to the complaint, defendants created the false impression that they possessed reliable information pertaining to Rocket’s projected timeline for the Company’s RP-A501 Phase 2 pivotal trial for the treatment of Danon disease to meet its required endpoints, as well as the safety of the drug and the trial as amended. In truth, Rocket’s optimistic reports pertaining to the trial’s ascribed timeline and safety profile fell short of the reality; ultimately, at least one patient enrolled in the study suffered from a Serious Adverse Event (SAE) and died, following Rocket’s veiled amendment to the trial’s protocol that introduced a novel immunomodulatory agent, a C3 inhibitor, to the pretreatment regimen, which halted enrollment and caused the trial to be place on hold by the FDA.

The complaint alleges that on May 27, 2025, Rocket published a press release providing an update on the Company’s Phase 2 Clinical Trial of RP-A501, including that a patient enrolled in the trial experienced an unexpected Serious Adverse Event (SAE). On this news, the company's stock fell from a closing market price of $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025.

What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Rocket Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/